Screener
Vir Biotechnology, Inc. VIR Research and development expenses
Research and development expenses at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept vir:AccruedResearchAndDevelopmentExpenseCurrent.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Research and development expenses | $35,465 | $35,299 |
| Payroll and related expenses | 13,957 | 28,724 |
| Excess funds payable under grant agreements | 1,832 | 1,825 |
| Operating lease liabilities, current | 9,137 | 8,798 |
| Other professional and consulting expenses | 9,009 | 3,327 |
| Other accrued expenses | 7,807 | 5,039 |
| Total accrued and other liabilities | $77,207 | $83,012 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s research and development expenses?
- Vir Biotechnology, Inc. (VIR) reported research and development expenses of $35.47M in Q2 2026.
- How has Vir Biotechnology, Inc.'s research and development expenses changed year-over-year?
- Vir Biotechnology, Inc.'s research and development expenses decreased by 9.8% year-over-year, from $39.33M to $35.47M.
- What does research and development expenses mean?
- Research and development expenses as reported by Vir Biotechnology, Inc. Common Stock.
Ask your AI about Vir Biotechnology, Inc.'s research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude